James reaffirmed its Outperform rating and $175.00 price target for Natera (NASDAQ:NTRA), following updates to oncology guidelines that could impact the company's cancer testing product, Signatera.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback